Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
BMI Calculator
Collaborate
About
EQOH
Careers
Contact Us
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Work With Us
EMJ Interactive
EMJ GOLD
CME
search
Join
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Mean Arterial Pressure (MAP) Calculator
BMI Calculator
Collaborate
About
EQOH
Careers
Contact Us
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Work With Us
EMJ Interactive
EMJ GOLD
CME
Join
FREE
Search type
Keyword
Author
EMJ GOLD
Filter
News
Articles
Podcasts
Infographics
Advertise With Us
Advertise With Us
Latest News
All News
EMJ GOLD
FDA approves first-in-class drug for rare skin disease
EMJ GOLD
AstraZeneca asthma drug succeeds in oesophagus disease trial
EMJ GOLD
J&J wins FDA nod for Imaavy in rare blood disorder
EMJ GOLD
Month in pharma news, explained – August 2026
Latest Articles
All Articles
EMJ GOLD
Why great therapies still fail to reach patients
A breakthrough in the lab does not guarantee a breakthrough for patients. So what gets in the way between approval and access?
EMJ GOLD
5 minutes with Dr Jamie L Weiss, Alnylam
Jamie L Weiss, Director, Global Medical Communications and Publications, Rare Disease, talks AI, rare diseases and more.
EMJ GOLD
GLP-1s: Cannes, culture and lessons from oncology
Claire Gillis, CEO, VML Health, explores how GLP-1s could transform medicine, echoing the cancer care revolution.
EMJ GOLD
One to watch: Multiple myeloma at EHA 2026
Ester in ’t Groen, TA Head, Haematology, J&J Innovative Medicine, discusses how treatment advances are transforming care.
Latest Podcasts
All Podcasts
EMJ GOLD
Richard Shotton on behaviour, bias and better pharma marketing
Behavioural science expert and Astroten founder Richard Shotton explores how behavioural science can improve pharmaceutical marketing.
EMJ GOLD
Rafal Kaminski on epilepsy, innovation and equity
Rafal Kaminski, Chief Scientific Officer, Angelini, explores how new science is reshaping brain health and what that means for patients.
EMJ GOLD
Hideki Garren on rethinking multiple sclerosis care
Hideki Garren explores how our understanding of MS is evolving, the challenge of measuring disease progression and what the future holds.
EMJ GOLD
The 2026 pharma forecast
Predictions you won’t want to miss from industry experts. Unpack opportunities, threats and unknowns.
Latest Infographics
All Infographics
EMJ GOLD
The truth about pharma emails: what HCPs really think
EMJ GOLD
How HCPs consumed medical content in 2025
EMJ GOLD
How well do you know medical affairs?
EMJ GOLD
How well do you know pharma marketing?
We’ve noticed you’re accessing
from
North/South America.
View
View